Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small-Cell Lung Carcinomas

Hui Yu, Qinghua Xu, Fang Liu, +3

Journal of Thoracic Oncology

A Mouse Model of Cholestasis-Associated Cholangiocarcinoma and Transcription Factors Involved in Progression

Heping Yang, Tony W.H. Li, Jian Peng, +4

Gastroenterology

Transcription Factors InvolvedTumor BiologyMalignant DiseaseBiliary TractMedicine +10

FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis

Qiqiao Du, Pan Liu, Chunyu Zhang, +12

Cell Death and Disease

miR‐125a‐3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor–positive breast cancer

Lufeng Zheng, Meng Xia, Xiaoman Li, +6

The FASEB Journal

Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer

Lufeng Zheng, Xiaoman Li, Meng Xia, +7

Molecular and Cellular Endocrinology

Breast OncologyEndogenous Rna NetworksMedicineNatural SciencesMolecular Biology +7

TBLR1 is a novel prognostic marker and promotes epithelial–mesenchymal transition in cervical cancer

Jing Wang, Jianping Ou, Yu Guo, +6

British Journal of Cancer

Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy

Yizuo Chen, Canming Chen, Benlong Yang, +7

Cancer Letters

Breast OncologyBreast Cancer ResponseMedicineHormonal ReceptorBreast Cancer +6

Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling

Lili Guo, Bo Zhou, Zhengqing Liu, +7

Tumor Biology

Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer

Bo Zhou, Hongbin Xu, Meng Xia, +15

Frontiers of Medicine

Mir-9 PromotesSerous Ovarian CancerMedicinePathologyTumor Suppressor +6

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC

Meng Xia, Xuena Li, Yao Diao, +2

Translational Oncology